- Home
- USIO vs IRD Comparison
USIO vs IRD Comparison
Compare USIO & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USIO
- IRD
- Stock Information
- Founded
- USIO 1998
- IRD 2018
- Country
- USIO United States
- IRD United States
- Employees
- USIO N/A
- IRD N/A
- Industry
- USIO Investment Bankers/Brokers/Service
- IRD
- Sector
- USIO Finance
- IRD
- Exchange
- USIO Nasdaq
- IRD NYSE
- Market Cap
- USIO 37.8M
- IRD 36.1M
- IPO Year
- USIO N/A
- IRD N/A
- Fundamental
- Price
- USIO $1.61
- IRD $1.13
- Analyst Decision
- USIO Strong Buy
- IRD Strong Buy
- Analyst Count
- USIO 2
- IRD 1
- Target Price
- USIO $5.00
- IRD $8.00
- AVG Volume (30 Days)
- USIO 795.8K
- IRD 159.2K
- Earning Date
- USIO 03-26-2025
- IRD 02-15-2025
- Dividend Yield
- USIO N/A
- IRD N/A
- EPS Growth
- USIO N/A
- IRD N/A
- EPS
- USIO 0.13
- IRD N/A
- Revenue
- USIO $81,027,258.00
- IRD $8,381,000.00
- Revenue This Year
- USIO $2.94
- IRD N/A
- Revenue Next Year
- USIO $14.59
- IRD $29.37
- P/E Ratio
- USIO $12.37
- IRD N/A
- Revenue Growth
- USIO N/A
- IRD N/A
- 52 Week Low
- USIO $1.24
- IRD $0.81
- 52 Week High
- USIO $2.92
- IRD $2.77
- Technical
- Relative Strength Index (RSI)
- USIO 42.91
- IRD N/A
- Support Level
- USIO $1.77
- IRD N/A
- Resistance Level
- USIO $1.96
- IRD N/A
- Average True Range (ATR)
- USIO 0.21
- IRD 0.00
- MACD
- USIO -0.10
- IRD 0.00
- Stochastic Oscillator
- USIO 3.33
- IRD 0.00
About USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for the Output Solutions operations.
About IRD OPUS GENETICS INC
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.